FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
FDA-APPROVED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS
Generic Brand Strength Form Adult Dose
Angiogenesis inhibitor
bevaci–
zumab		 Avastin 100mg, 
400mg		 soln for IV infusion after
dilution		 15mg/kg once every 3wks with
carboplatin/paclitaxel
bevacizumab-awwb Mvasi 100mg, 400mg soln for IV infusion after dilution 15mg/kg every 3wks with carboplatin/paclitaxel until disease progression or unacceptable toxicity
bevacizumab-bvzr Zirabev 100mg, 400mg soln for IV infusion after dilution 15mg/kg every 3wks with carboplatin/paclitaxel
ramuci–
rumab		 Cyramza 10mg/mL soln for IV infusion after
dilution		 Exon 19 deletions or exon 21 mutations: 10mg/kg every 2wks with erlotinib. Disease progression: 10mg/kg on Day 1 of a 21-day cycle prior to docetaxel. Both: continue until disease progression or unacceptable toxicity.
Antimetabolites
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after
reconstitution		 Give with cisplatin 100mg/m² administered on Day 1 after gemcitabine. 1000mg/m² on Days 1, 8, and 15 of each 28-day cycle; or 1250mg/m² on Days 1 and 8 of each 21-day cycle
Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion
metho–
trexate		 — 25mg/mL soln for IV, IM, intra-
arterial, or intrathecal
administration after
dilution		 See drug monograph and manufacturer’s full labeling
1g pwd for IV, IM, intra-
arterial, or intrathecal
administration after
dilution
Trexall 5mg, 7.5mg, 10mg, 15mg scored tabs
pemetrexed Alimta 100mg, 500mg pwd for IV infusion after
reconstitution and
dilution		 CrCl ≥45mL/min: 500mg/m² on Day 1 of each 21-day cycle. In combination with pembrolizumab and platinum chemotherapy: treat for 4 cycles; following platinum-based therapy completion, give pemetrexed with or without pembrolizumab until disease progression or unacceptable toxicity. In combination with cisplatin: treat for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance, recurrent NSCLC: continue until disease progression or unacceptable toxicity. Supplement with oral folic acid and IM vitamin B12 one week prior to 1st pemetrexed dose, during treatment, and for 21 days after last dose. Pretreat with dexamethasone for 3 consecutive days, beginning the day before each pemetrexed dose.
Antimicrotubule agents
docetaxel Taxotere 20mg/mL soln for IV infusion after
dilution		 Infuse over 1hr once every 3wks. After platinum therapy failure: 75mg/m². Chemotherapy-naive: 75mg/m² followed by cisplatin (see full labeling).
paclitaxel — 6mg/mL soln for IV infusion after
dilution		 135mg/m² IV plus cisplatin
every 3wks
paclitaxel [bound to albumin
(human)]		 Abraxane 100mg/
 vial		 pwd for IV infusion after
reconstitution		 100mg/m² on Days 1, 8, and 15 of each 21-day cycle with carboplatin
vinorelbine — 10mg/mL soln for IV inj after
dilution		 Monotherapy: 30mg/m² once
weekly. Combination therapy: 25mg/m²
on Days 1, 8, 15, and 22 of a 28-day cycle with cisplatin (100mg/m²) given on Day 1 of each 28-day cycle; or 30mg/m² once weekly with cisplatin (120mg/m²) given on Days 1 and 29, then every 6wks.
CTLA-4 Blocking Antibody
ipilimumab Yervoy 5mg/mL soln for IV infusion Metastatic NSCLC with PD-L1: 1mg/kg every 6wks with nivolumab 3mg/kg every 2wks. Metastatic or recurrent NSCLC: 1mg/kg every 6wks with nivolumab 360mg every 3wks and histology-based platinum doublet chemotherapy every 3wks for 2 cycles. Continue with nivolumab until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression.
HUMAN EGFR INHIBITOR
necitumumab Portrazza 800mg/50mL soln for IV infusion after dilution 800mg on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity
Kinase Inhibitors
afatinib Gilotrif 20mg, 30mg, 40mg tabs 40mg once daily on empty stomach; continue until disease progression or unacceptable toxicity
alectinib Alecensa1 150mg caps 600mg twice daily until disease
progression or unacceptable
toxicity
brigatinib Alunbrig1 30mg, 90mg, 180mg tabs 90mg once daily for first 7 days, then increase to 180mg once daily; continue until disease progression or unacceptable toxicity.
capmatinib Tabrecta6 150mg, 200mg tabs 400mg twice daily.
ceritinib Zykadia1 150mg hard gel caps, tabs 450mg once daily with food until disease progression or unacceptable toxicity; discontinue if 150mg once daily with food not tolerated
crizotinib Xalkori1,5 200mg, 250mg caps 250mg twice daily until disease progression or unacceptable toxicity
dabrafenib Tafinlar4 50mg, 75mg caps In combination with trametinib: 150mg twice daily (approx. 12hrs apart); continue until disease recurrence or unacceptable toxicity
dacomitinib Vizimpro2 15mg, 30mg, 45mg tabs 45mg once daily until disease progression or unacceptable toxicity
erlotinib Tarceva2 25mg, 100mg, 150mg tabs 150mg once daily until disease progression or unacceptable toxicity
gefitinib Iressa2 250mg tabs 250mg once daily until disease progression or unacceptable toxicity
lorlatinib Lorbrena1 25mg, 100mg tabs 100mg once daily until disease progression or unacceptable toxicity
osimertinib Tagrisso2,3 40mg, 80mg tabs 80mg once daily. Metastatic: treat until disease progression or unacceptable toxicity. Adjuvant: treat until disease recurrence, unacceptable toxicity, or for up to 3yrs.
pralsetinib Gavreto7 100mg caps 400mg once daily until disease progression or until unacceptable toxicity
selpercatinib Retevmo7 40mg, 80mg hard gel caps <50kg: 120mg twice daily (approx. every 12hrs). ≥50kg: 160mg twice daily (approx. every 12hrs). Continue until disease progression or unacceptable toxicity.
trametinib Mekinist4 0.5mg, 2mg tabs In combination with dabrafenib: 2mg once daily (approx. 24hrs apart); continue until disease recurrence or unacceptable toxicity
PD-1/PD-L1 Blocking Antibodies
atezolizumab Tecentriq 60mg/mL soln for IV infusion after
dilution		 Single agent: 840mg every 2wks, or 1200mg every 3wks, or 1680mg every 4wks. In combination with platinum-based chemotherapy: 1200mg every 3wks; after 4–6 cycles of chemotherapy completed, and if bevacizumab discontinued, give 840mg every 2wks, or 1200mg every 3wks, or 1680mg every 4wks. Continue until disease progression or unacceptable toxicity. In combination therapy: administer atezolizumab prior to chemotherapy and bevacizumab when given on the same day (see full labeling).
durvalumab Imfinzi 50mg/mL soln for IV infusion after
dilution		 Stage III NSCLC (<30kg): 10mg/kg every 2wks; (≥30kg): 10mg/kg every 2wks or 1500mg every 4wks. Continue until disease progression, unacceptable toxicity, or max 12mos.
nivolumab Opdivo 10mg/mL soln for IV infusion after
dilution		 NSCLC with PD-L1: 3mg/kg every 2wks with ipilimumab (1mg/kg every 6wks); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression. Metastatic or recurrent NSCLC: 360mg every 3wks with ipilimumab (1mg/kg every 6wks) and histology-based platinum doublet chemotherapy every 3wks (for 2 cycles only); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression. NSCLC (single-agent): 240mg every 2wks or 480mg every 4wks until disease progression or unacceptable toxicity. Combination therapy: administer Opdivo first followed by ipilimumab, and/or platinum doublet chemotherapy on the same day.
pembrolizumab Keytruda 25mg/mL soln for IV infusion after
dilution		 200mg every 3wks or 400mg every 6wks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. In combination with chemotherapy: give prior to chemotherapy when given on the same day (see full labeling).
Photosensitizing agent
porfimer Photofrin 75mg pwd for IV inj after
reconstitution		 2mg/kg then illumination with
laser light 40−50hrs following
injection
NOTES

1 For ALK-positive metastatic NSCLC only.

2 For metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations only.

3 For metastatic NSCLC with EGFR T790M mutation only.

4 For metastatic NSCLC with BRAF V600E mutation only.

5 For ROS1-positive metastatic NSCLC only.

6 For metastatic NSCLC with mutation that leads to MET exon 14 skipping only.

7 For RET fusion-positive metastatic NSCLC only.

Not an inclusive list of medications, official indications, and/or dosing details. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 3/2021)

Topics:

Lung Cancer Oncology Respiratory and Thoracic Cancers